PUBLICATION
Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery
- Authors
- Morgan, E., Gamble, J.T., Pearce, M.C., Elson, D.J., Tanguay, R.L., Kolluri, S.K., Reich, N.O.
- ID
- ZDB-PUB-200506-18
- Date
- 2019
- Source
- Apoptosis : an international journal on programmed cell death 24: 529-537 (Journal)
- Registered Authors
- Tanguay, Robyn L.
- Keywords
- Apoptosis, Bcl-2, Hollow gold nanoshells, NuBCP, Peptide delivery, Resistant cancer
- MeSH Terms
-
- Gold/chemistry*
- Apoptosis/drug effects
- Drug Liberation
- Drug Resistance, Neoplasm/drug effects
- Oligopeptides/chemistry
- Oligopeptides/pharmacology
- Humans
- Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors
- Proto-Oncogene Proteins c-bcl-2/metabolism*
- Nanoshells/chemistry*
- Cell Line, Tumor
- Laser Therapy
- Xenograft Model Antitumor Assays
- Drug Delivery Systems*
- Lung Neoplasms/metabolism
- Lung Neoplasms/pathology
- Lung Neoplasms/therapy
- Animals
- Cell Survival/drug effects
- Zebrafish/growth & development
- Zebrafish/physiology
- Drug Carriers/chemistry
- Drug Carriers/pharmacology
- Paclitaxel/pharmacology
- Antineoplastic Agents/chemistry*
- Antineoplastic Agents/pharmacology
- PubMed
- 30879165 Full text @ Apoptosis
Citation
Morgan, E., Gamble, J.T., Pearce, M.C., Elson, D.J., Tanguay, R.L., Kolluri, S.K., Reich, N.O. (2019) Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery. Apoptosis : an international journal on programmed cell death. 24:529-537.
Abstract
Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping